Two new grants from the Leukemia & Lymphoma Society will support Weill Cornell Medicine’s pathbreaking research on the origins of lymphomas and on treatments that exploit these cancers’ biological vulnerabilities.
Weill Cornell Medicine investigators have developed a technique to help surgeons reconstruct more natural-looking nipples for patients who have undergone breast reconstruction after mastectomy to treat breast cancer.
Nearly 90% of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.
A small but significant metabolic difference between human and mouse lung tumor cells has been discovered by Weill Cornell Medicine researchers, explaining a discrepancy in previous study results and pointing toward new strategies for developing cancer treatments.
The $3.5 million grant will go toward the improvement of screening and preventive treatment of cervical cancer for women living with HIV in low-resource countries.
Katherine King, institutional equity officer at SUNY Upstate Medical University, in Syracuse, New York, will join Cornell as the associate vice president for the Office of Institutional Equity and Title IX, effective Nov. 1.
The activity of a gene called CIART is a key factor in the establishment of the viral infection that causes COVID-19, according to a study from researchers at Weill Cornell Medicine and New York University Grossman School of Medicine.
Researchers studying large-scale artificial intelligence, microbial biomanufacturing and causal inference methods are among the Cornell researchers who recently received National Science Foundation Faculty Early Career Development Awards.